Japan medical insurance rider product matrix

TL;DR

Japanese medical insurance is a specialty franchise within the broader life-insurance industry, with one foreign affiliate (Aflac Japan) historically holding roughly 70% of the new cancer-insurance market, several other foreign affiliates (AIA Japan, Manulife Japan, Prudential Japan) running large medical / protection books, the non-life big-three life-subsidiary platforms (Tokio Marine & Nichido Life / Anshin Seimei lineage, Sompo Himawari Life, Mitsui Sumitomo Aioi Life) competing for medical / rider share, and the life big-four mutuals (Nippon Life, Dai-ichi Life, Sumitomo Life, Meiji Yasuda) bundling medical riders into whole-life and term franchises. The product offering can be reduced to a small set of axes that determines competitive position: (1) primary line — cancer-specific (Aflac dominance), medical (per-day hospital + lump-sum surgery), or rider (attached to base whole-life / term); (2) premium-payment structure — whole-life payment versus term payment versus short-payment-period 短期払 designs; (3) benefit type — lump-sum (一時金), per-day hospital benefit (入院日額), expense-reimbursement (実損填補), or a combination; (4) 先進医療 (advanced-medical-treatment) rider — almost universal but with coverage-cap differences; (5) channel mix — tied sales force, agency, bancassurance, or direct online; and (6) 解約返戻金 (surrender value) design — savings-style (with cash value) versus pure protection (no surrender value). The competitive heat-map sits at cancer (Aflac vs Sompo Himawari vs AIA vs MS Aioi), pure medical (Aflac vs Sompo Himawari vs Tokio Marine Anshin vs Orix / Medicare-style players outside the matrix), and rider-attached medical (life big-4 vs foreign affiliates).

Wiki route

This matrix sits under insurance INDEX and is the product companion to the medical / cancer insurance product economics entry. Read it together with the Japan life insurance big four entry, the life big-four overlay matrix, foreign-life-affiliate positioning, the internet life insurance business model, the life insurance channel mix, the agency / brokerage Japan landscape, bancassurance economics Japan, the bancassurance distribution overlay matrix, the kyosai vs FSA perimeter matrix for the cooperative-perimeter alternative, and the Sony Life group life operating model for the lifeplanner-channel context.

The clean carrier anchors for this matrix are Aflac Japan, AIA Japan, Manulife Japan, Prudential Japan, AXA Japan, Tokio Marine & Nichido Life (with the Anshin Seimei franchise history), Sompo Himawari Life, Mitsui Sumitomo Aioi Life, Nippon Life, Dai-ichi Life, Sumitomo Life, Meiji Yasuda, Sony Life, Lifenet, SBI Life, and Kampo Life.

Why this matrix matters

Reading a Japanese household’s medical-coverage choice means picking among at least three different product architectures bundled under the umbrella “医療保険”:

1. Cancer-specific (がん保険) — a separate product line with separate underwriting, separate waiting periods, and separate premium curves. Aflac built the modern Japanese cancer-insurance market in the 1970s and has held a roughly 70% share of new business in the segment for decades.
2. General medical (医療保険) — hospital-stay per-day benefit plus surgery lump-sum plus rider menu (advanced medical, three major diseases, hospitalisation lump-sum). The competitive heat is hottest here.
3. Rider attached to whole-life or term protection (医療特約 / 入院特約) — bundled into a base life policy from the life big-4 mutuals and from foreign affiliates running protection-bundle plans (Sony Life lifeplanner, Prudential, Manulife).

The matrix below decomposes each axis. Specific product names, premium rates, channel commissions, and underwriting limits are date-specific and should be confirmed against each carrier’s product brochure, the FSA solicitation-rule disclosure, and the carrier’s annual / disclosure document.

Aflac Japan — cancer-specific dominance and modern medical menu

Aflac Japan (Aflac Life Insurance Japan / アフラック生命保険) is the historical and current leader in Japanese cancer insurance. The structural features: a specialty product line dedicated to cancer (がん保険) with broad agent and bancassurance distribution including a long-running Japan Post Bank tie-up, supplementary medical (医療保険) products that bundle in cancer benefits or stand alone, and a tied-sales-force / agency hybrid distribution. Aflac built the original Japanese cancer-insurance product in 1974 and the modern menu is the most differentiated by rider (cancer treatment lump-sum, hospitalisation-by-day benefit during cancer treatment, advanced-medical (先進医療), outpatient cancer-treatment benefit). The premium-payment structure is normally whole-life-payment (終身払) or short-payment-period (短期払) with the choice affecting the level premium curve.

AIA Japan — multi-line protection franchise

AIA Japan (AIA Group’s Japanese subsidiary, formerly AIG Star Life heritage) runs a full protection franchise with cancer, medical, term, whole-life, and rider menu. AIA’s competitive position in Japan combines agency distribution, partner-bank bancassurance, and a financial-adviser / lifeplanner-adjacent sales force. The medical / cancer book is a major contributor to new business value.

Tokio Marine Anshin lineage — non-life big-3 life affiliate

Tokio Marine & Nichido Life (Anshin Seimei legacy) is the life affiliate of the Tokio Marine Holdings non-life group. The medical / cancer franchise was historically anchored by the “メディカル Kit R” series and successor product families that competed directly with Aflac in medical and with Sompo Himawari in cross-line distribution. The non-life parent’s nationwide agency network is the structural distribution advantage.

Sompo Himawari Life — non-life big-3 life affiliate

Sompo Himawari Life (損保ジャパン日本興亜ひまわり生命 / present-day Sompo Himawari Life) is the life subsidiary of Sompo Holdings. The structural feature on medical is a strong rider-product franchise with cancer, three-major-disease cover, women-specific medical, and 先進医療 riders. Distribution combines tied sales force, agency, and partner-bank channels.

Mitsui Sumitomo Aioi Life — MS&AD life affiliate

Mitsui Sumitomo Aioi Life is the MS&AD group life subsidiary. The medical / rider franchise sits inside the MS&AD distribution ecosystem with access to both MSI and ADI agent networks. The product menu covers medical, cancer riders, term, whole-life, and individual annuity.

Foreign affiliates beyond Aflac and AIA — Manulife, Prudential, MetLife, AXA

Manulife Japan and Prudential Japan run protection-led franchises with lifeplanner / FA-style sales forces. The medical / rider product menu is anchored by whole-life and term protection with medical riders rather than by stand-alone medical or cancer products. AXA Japan (旧アクサ生命) runs a multi-channel medical / protection franchise. MetLife Japan, AIG Life Japan, and the smaller foreign affiliates round out the competitive set.

Life big-4 mutuals — bundled medical riders inside whole-life

The four big mutuals — Nippon Life, Dai-ichi Life, Sumitomo Life, Meiji Yasuda — distribute medical cover predominantly as riders to whole-life or term base policies through their tied sales forces. Sumitomo Life’s Vitality-branded wellness-linked product is the most differentiated structural feature among the four; the others compete on rider menu breadth, sales-force trust, and corporate-group cross-sell. Each runs stand-alone medical / cancer products through agency and bancassurance routes for the segment that prefers specialty cover.

Big comparison matrix table

The matrix below lists axes that differentiate the principal carriers in the Japanese medical / cancer specialty. Specific share, premium, and product names are date-specific and should be confirmed against each carrier’s current disclosure.

Carrier identity and franchise

Primary product line — cancer / medical / rider split

Premium-payment structure

Benefit type by product

Channel mix

Underwriting and pricing structure

解約返戻金 (surrender value) design

先進医療 (advanced-medical-treatment) rider detail

Foreign-currency medical / annuity overlay

Conceptual market share signal

Historical and structural context

The current Japanese medical-insurance structure reflects several decades of product and regulatory evolution:

• 1974 Aflac cancer-insurance entry introduced specialty cancer insurance to the Japanese market and built the segment. Aflac’s distribution combined corporate / employer group sales and agency.
• 1995 Insurance Business Act revision modernised the licensing regime and laid the foundation for foreign-affiliate expansion in the protection / medical specialty.
• 1996–2001 third-sector liberalisation opened the medical / cancer / nursing specialty to foreign affiliates and to non-life-group life subsidiaries on a level playing field. The third sector (第三分野) is the regulatory category for medical / cancer / nursing products that sit between life (第一分野) and non-life (第二分野).
• 2001 onward Japan Post Bank distribution alliance scaled Aflac cancer-insurance reach through the Japan Post Bank counter network.
• Late 2000s onward 先進医療 rider standardisation made the advanced-medical-treatment rider an industry-standard add-on with high actual-cost caps.
• 2010s short-payment-period (短期払) product wave offered 60-payment / 65-payment level-premium structures that finish premium payment before retirement, with whole-life cover continuing.
• 2010s foreign-currency-bundle expansion combined foreign-currency whole-life with medical riders through bancassurance, distributed by Dai-ichi Frontier Life, MS Primary Life, Manulife, and similar.
• 2015 onward 引受基準緩和 (limited-underwriting) expansion opened medical / cancer cover to older / mildly-impaired applicants who would have been declined under standard underwriting.
• 2020s wellness-linked products (Sumitomo Life Vitality and similar) link premium discounts to health behaviour and biometric data.
• 2025 ESR rollout under the FSA economic-value-based solvency regime affects the capital treatment of medical / cancer liability cash flows for all FSA-perimeter carriers — see economic-value-based solvency and ESR.

Decision use

Use this matrix when reading the Japanese medical-insurance competitive set against each other rather than against the broader life industry. Practical questions:

• Cancer specialty vs medical bundle. Aflac dominates stand-alone cancer; multiple carriers compete on medical. A household buying cancer-specific cover faces a different competitive set than one buying general medical.
• Surrender-value design. Modern medical / cancer products are designed as pure protection with no significant surrender value. Older policies may have surrender value built in. The choice affects premium curve and tax treatment.
• Whole-life vs short-payment. Short-payment-period products finish premium payment before retirement at the cost of higher early-year premiums. The 解約返戻金 (surrender value) trajectory and the protection-cost economics differ.
• Foreign-currency medical bundle. USD-denominated whole-life with medical rider transfers FX risk to the policyholder but offers higher cash-value-projection grammar. The bancassurance distribution route is the principal channel.
• Channel suitability. Tied sales force is the dominant channel for life-big-4 medical riders; agency / shop is the dominant channel for foreign-affiliate stand-alone medical / cancer; bancassurance dominates foreign-currency bundle; direct online is the Lifenet / SBI Life lane.
• Kyosai-perimeter alternative. Many households hold both FSA-perimeter medical / cancer cover and kyosai medical rider (JA共済 / Zenrosai / Kenmin-kyosai / COOP共済). See the kyosai vs FSA perimeter matrix for the cooperative-perimeter overlay.
• MHLW national-health-insurance interaction. Japanese medical insurance products sit on top of the public health insurance system (公的医療保険) where MHLW caps out-of-pocket via the 高額療養費 system. The supplementary-cover product design assumes this base layer.

Boundary cases / caveats

• Numbers are conceptual. Market shares (notably Aflac’s ~70% cancer share), premium rates, benefit caps, and rider availability change with each product cycle and disclosure period. Sources are FSA, Seiho industry publications, each carrier’s product brochures and integrated / disclosure documents, and MHLW publications on public health insurance.
• Aflac cancer share. The ~70% figure is widely cited industry shorthand for new cancer-insurance market share and has held over many years. Specific recent vintages should be confirmed against Aflac’s disclosure and Seiho industry data.
• Carrier-naming history. Several carriers have renamed or merged (Anshin Seimei → Tokio Marine & Nichido Life lineage; Sompo Japan Nipponkoa Himawari Life → Sompo Himawari Life; AIG Star Life → AIA Japan lineage; Sumitomo Life Vitality is a wellness-linked product line, not a separate carrier). The matrix uses the current entity name.
• Third-sector (第三分野). Medical, cancer, and nursing products sit in the third sector for regulatory purposes — between life (第一分野) and non-life (第二分野). All FSA-perimeter life carriers (and non-life carriers via life subsidiaries) participate.
• Foreign-currency products. Foreign-currency whole-life with medical rider transfers FX risk to the policyholder. Conduct rules require dedicated suitability and explanation for these products, especially for elderly customers. See bancassurance economics Japan.
• Online-direct contrast. Lifenet and SBI Life do not appear as primary competitors in the cancer-specialty matrix above but are growing players in pure medical / cancer specialty at lower premium points. See the internet life model.
• Wellness-linked products. Vitality and similar wellness-linked product menus reward behaviour with premium discounts. The structural feature affects long-run pricing and persistency but does not change the product-line classification.
• Surrender value and tax. 解約返戻金 (surrender value) on medical / cancer products is generally suppressed by design; the cash-value tax treatment on whole-life base policies follows the standard income-tax code.
• Public health insurance base. Japanese supplementary medical products assume the public-health-insurance base. Changes in 高額療養費 (high-cost medical treatment) cap rules can affect supplementary-product economics.
• Kampo Life product menu. Subject to special-law approval constraints. Read the Kampo entry separately.

Related

• INDEX
• medical-cancer-insurance-product-economics
• japan-life-insurance-big-four
• japan-life-big-four-overlay-comparison-matrix
• foreign-life-affiliate-japan-positioning
• internet-life-insurance-business-model
• life-insurance-channel-mix
• insurance-agency-and-brokerage-japan
• bancassurance-economics-japan
• japan-bancassurance-distribution-overlay-matrix
• japan-kyosai-vs-fsa-insurance-perimeter-matrix
• sony-life-group-life-operating-model
• economic-value-based-solvency
• esr-economic-value-solvency
• kampo-japan-post-insurance
• aflac-japan
• aia-life-japan
• manulife-japan
• prudential-japan
• axa-japan
• tokio-marine-nichido-life
• sompo-himawari-life
• mitsui-sumitomo-aioi-life
• nippon-life
• dai-ichi-life
• sumitomo-life
• meiji-yasuda
• sony-life
• lifenet
• sbi-life
• kampo-life
• FinWiki index

Sources

• FSA: Regulated entities and licensed insurers.
• Seiho: Life Insurance Association member-company list.
• MHLW: Public health insurance system (公的医療保険).
• Aflac Japan: corporate information.
• AIA Japan: corporate information.
• Tokio Marine & Nichido Life: corporate / product disclosure.
• Sompo Himawari Life: corporate information.
• Mitsui Sumitomo Insurance: corporate information.
• Aioi Nissay Dowa Insurance: corporate information.
• Manulife Japan: corporate information.
• Prudential Japan: corporate information.
• Nippon Life: global IR / integrated reports.
• Dai-ichi Life Holdings: IR.
• Sumitomo Life: IR / integrated reports.